Laetitia Odeyer

Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer

S. Michiels, A. Thompson, F. Jamen, 2022, BMC cancer.

Ribosome biogenesis‐based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group

I. Treilleux, I. Ray-Coquard, V. Marcel, 2022, Molecular oncology.